Glucagon-like Peptide-1 receptor agonists rarely cause de novo acute pancreatitis but often result in serum lipase elevations of unclear clinical significance
- 25 December 2025
- journal article
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 299-301
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Discordance Between Radiological and Clinical Findings Among Patients Presenting With Elevated Lipase and Abdominal PainClinical and Translational Gastroenterology, 2025
- Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological statusSignal Transduction and Targeted Therapy, 2025
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Interpretation of serum pancreatic enzymes in pancreatic and nonpancreatic conditionsCurrent Opinion in Gastroenterology, 2023
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic EnzymesCell Reports, 2016
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein SynthesisDiabetes, 2014
- Distinct function of the head region of human pancreas in the pathogenesis of diabetesIslets, 2013